Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors
Keywords
-
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-12
DOI
10.1245/s10434-019-07927-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
- (2019) Chao Liu et al. CLINICAL SCIENCE
- Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer
- (2019) Yanbing Wang et al. Journal of Biomedical Nanotechnology
- Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy
- (2018) Yosuke Mukai et al. ANNALS OF SURGICAL ONCOLOGY
- Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer
- (2018) Jinnian Ge et al. VIRCHOWS ARCHIV
- CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells
- (2018) Yu Liang et al. Oncogenesis
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
- (2017) Niklas Landberg et al. HAEMATOLOGICA
- Targeting metastasis-initiating cells through the fatty acid receptor CD36
- (2016) Gloria Pascual et al. NATURE
- A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
- (2016) Takuya Sakamoto et al. PLoS One
- A population-based study of the epidemiology of pancreatic cancer: a brief report
- (2015) R.S. Raju et al. Current Oncology
- Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios
- (2015) Sadaki Asari et al. SURGERY TODAY
- Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma
- (2015) Aritro Nath et al. Scientific Reports
- Commentary on Myers et al.: Growing role of the innate immunity receptor CD36 in central nervous system diseases
- (2014) Lidia Garcia-Bonilla et al. EXPERIMENTAL NEUROLOGY
- Cancer Stem Cell-Specific Scavenger Receptor CD36 Drives Glioblastoma Progression
- (2014) James S. Hale et al. STEM CELLS
- Alteration of the Intrinsic Apoptosis Pathway Is Involved in Notch-induced Chemoresistance to Gemcitabine in Pancreatic Cancer
- (2013) Xiao Du et al. ARCHIVES OF MEDICAL RESEARCH
- miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1
- (2013) Y Iwagami et al. BRITISH JOURNAL OF CANCER
- Japan Pancreatic Cancer Registry; 30th Year Anniversary
- (2012) Shinichi Egawa et al. PANCREAS
- Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection
- (2011) Daisaku Yamada et al. ANNALS OF SURGICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More